tbuckley/cabot-search huggingface dataset:
Cabazitaxel in patients with advanced CRPC after docetaxel failure: Results of expanded program access (EAP) in Spain: Safety and efficacy.
Authors: Guillermo De Velasco, Luis Anton Aparicio, Emilio Esteban, Quionia Perez, Alfredo Sanchez-Hernandez, Begoña Pérez-Valderrama, Norberto Batista, Juan Sepulveda, Daniel E. Castellano
Journal: Journal of Clinical Oncology (2012)

e15149 Background: Cabazitaxel is the new chemotherapy standard as second line in castrate resistant prostate cancer (CPRC) [Tropic Trial, Lancet 2010]. The aim of this study was to analyze the baseline characteristics and outcomes in a different cohort of patients (pts) from six hospitals in Spain within to EAP. Methods: We report a cohort of 65 pts including in EAP trial, who have progressed on or after docetaxel-based chemotherapy. Cabazitaxel was administered a standard dose of 25 mg/m2 IV q3wks. All pts had proven histology confirmation of prostate adenocarcinoma and progressive disease (radiologic and/or rising PSA) at the beginning of the treatment. Results: We collected data of 65 pts between 3-2011 to 12-2012. Median age was 63 years (range 45-83) and ECOG 0-1-2 in 26%-58%-16% respectively. Median basal PSA was 864 and Gleason grade was 7. Seventy-eight percent had bone metastases, 33% ganglionar metastases and 14% visceral metastases. Previous therapy was: hormonal, median 2 lines and chemotherapy was median of 1.6 lines. Thirty percent (20 pts) had received ketoconazole. Median of previous docetaxel dose was 1029 mg/m2(50-3750). Seventy percent of pts received G-CSF as primary prophylaxis in any cycle, 24% (16pts) had grade &gt;3 neutropenia and 6 pts (9%) had febrile neutropenia. Other toxicities were: g3 anemia 3pts (4,6%), g3 asthenia 5pts (7,7%), g3 diarrhea 1 pt (1,5%). No toxic death was reported. The PSA response rate to cabazitaxel was 64% (31pts) and the median of cabazitaxel cycles administered was 6 at last follow-up. Median progression free survival was 4.4 months (2.7-6.1). Conclusions: These results confirm the efficacy and safety of cabazitaxel in this setting. Similar baselines parameters to Tropic trial were observed. This data reflex that Cabazitaxel in CRPC pts after docetaxel failure require the use of G-CSF in daily clinical practice.
A community-based program for personalized cancer care using next-generation sequencing (NGS).
Authors: Shile Liang, Pranil Chandra, Zeqiang Ma, Debbie Haynes, James Prescott, Lisa H. Morrissey, Suzanne Fields Jones, David R. Spigel, Michael R. Savona, John D. Hainsworth, Jeffrey R. Infante, Howard A. Burris
Journal: Journal of Clinical Oncology (2013)

11102 Background: Despite growing interest and need, molecular profiling of tumor samples is largely unavailable in community cancer centers, where nearly 80% of cancer patients (pts) are treated. In 10/12, Sarah Cannon Research Institute (SCRI) launched a community-based molecular profiling program to: 1) better understand the molecular constituency of cancer patients, 2) identify appropriate pts for phase I and II clinical trials of targeted agents, and 3) identify pts with molecular abnormalities responsive to FDA-approved agents. Methods: Eligible pts consented to testing of available biospecimens, which were interrogated for alterations in 35 cancer-related genes using NGS (1000X average coverage) in a CLIA/CAP laboratory. Results were reported to the treating physician within 14 days and stored in a database to enable correlation with clinical outcomes. Results: As of 1/13, 209 pts had been enrolled with 84% having sufficient material for assay. At least 1 mutation was detected in 46% of tumors. Results in the 3 most commonly assayed tumor types are summarized (Table). Mutations for which there are FDA-approved targeted agents were found in 14 off-label tumors (EGFR 4, KIT 3, SMO 3, BRAF 2, HER2 2). 40 pts (27%) were subsequently enrolled in clinical trials; in 19 of these, assay results influenced clinical trial selection. Conclusions: This program provides molecular profiling data to community oncologists for clinical decision making. Experience to date indicates this information can be provided in a timely manner for incorporation into clinical practice. Profiling results will enable: 1) selection of pts with appropriate tumor targets for investigational targeted agents, 2) enhanced study enrollment, 3) evaluation of FDA approved targeted agents in off-label tumor types, and 4) correlation of treatment outcomes with patterns of tumor molecular abnormalities. [Table: see text]
Proliferation Kinetics of Subclones Carrying Point Mutations In the BCR-ABL TKD During TKI Treatment In CML Patients: Quantitative Monitoring by LD-PCR
Authors: Sandra Preuner, Margit Bernroitner, Gerlinde Mitterbauer, Christine Mannhalter, Susanne Herndlhofer, Wolfgang R Sperr, Gerald Webersinke, Peter Valent, Thomas Lion
Journal: Blood (2010)
Management of clinical stage I seminomatous testicular cancer: A report from SWENOTECA.
Authors: Torgrim Tandstad, Eva Cavallin-Stahl, Olav Dahl, Hege Sagstuen Haugnes, Carl Wilhelm Langberg, Anna Laurell, Jan Oldenburg, Ulrika K. Stierner, Arne Solberg, Karin Soderstrom, Olof Stahl, Najme Wall, Gabriella Elisabeth Cohn-Cedermark
Journal: Journal of Clinical Oncology (2014)

4508 Background: Clinical stage I seminoma testicular cancer is the most frequent presentation of testicular cancer. Current treatment option include surveillance (SURV) or adjuvant chemotherapy. Following a large randomized phase III study, 1 course of adjuvant carboplatin (AC) AUC7 became the preferred adjuvant treatment option. Methods: A risk-adapted protocol (SWENOTECA VII) was initiated in 2007, based on the proposed risk factors; invasion of rete testis and tumor size >4cm. Patients with 0-1 risk factor were recommended SURV, but could choose 1 course of AC (AUC7). Patients with 2 risk factors were recommended 1 course of AC, but could choose SURV. We also report treatment results from patients treated with AC in an earlier protocol during 2004-2007. Results: 839 patients were included in the SWENOTECA VII protocol. In addition 225 patients were treated with AC before 2007. Median follow-up is 4.0 years, 3.6 years for patients on SURV and 4.2 years for patients treated with AC. In total 675 patients were treated with AC, and 389 patients chose SURV. Complete information regarding risk factors was available in 946 patients. The relapse-rate (RR) following AC was 6.2 %; in patients without risk factors 2.7 % compared to 9.4 % in patients with 1-2 risk factors. In patients followed by SURV the RR was 10 %; in patients without risk factors 2.9 %, compared to 21.7 % in patients with 1-2 risk factors. Conclusions: In this modern, large, population-based prospective study we confirm the low relapse rate previously reported for patients with 0 risk factors on SURV, thus patients with no risk factors should be followed by SURV. The RR with AC was somewhat higher than reported in MRC TE19/EORTC 30982. This may be due to the risk-adapted approach, with a higher proportion of patients with 1-2 risk factors treated with AC. The RR following AC indicated a relatively modest effect in preventing relapse. Data regarding exact doses are being collected to assess if inadequate dosing may have affected the RR following AC.
Stereotactic body radiotherapy (SBRT) in patients with hepatocellular carcinoma with Child-Pugh class B.
Authors: Higinia Rosa Cardenes, Foster D Lasley, Paul Kwo, Susan M. Perkins, Mary A. Maluccio
Journal: Journal of Clinical Oncology (2012)

e14683 Background: Stereotactic body radiotherapy (SBRT) is a promising therapeutic modality in hepatocelular carcinoma (HCC). A Phase I trial was conducted at Indiana University (IU) in patients with Child Pugh Class (CPC) A and B. Based on our results, patients with CPC-B patients with score &lt;=7 continued enrollment in the phase II. We now present an interim analysis for this patient population. Methods: 14 patients with HCC with liver cirrhosis, CPC-B, were treated with SBRT in a Phase I-II trial at IU. All patients were scheduled to receive five fractions, 800 cGy per fraction (total dose 4000 cGy), 1-2 fractions per week. Dose was prescribed to the 80-90% isodose line covering the planning target volume (PTV). A modified RECIST criterion was used to determine local failure. Demographics, clinical variables, treatment –related toxicities within 90 days of end of treatment, and local control (LC) at 6 and 12 months were tabulated. Progression Free Survival (PFS), Time to Progression (TTP), and Overall Survival (OS) estimates were calculated using Kaplan-Meier methodology. This was an unplanned interim analysis. A formal interim analysis will take place later. Results: There were 13 males and 1 female; median age of 56.5 years (range 49-69). All patients had 1 treated lesion. Median (range) for gross tumor volume (GTV) (cc) was 40.1 (8.0-74.6); PTV volume (cc) was 120.1 (34.7-210.0); and uninvolved liver volume (cc) was 2137.9 (973.0-2796.0). There were 3 grade 4 toxicities, 1 each of hyperbilirubinemia, hypokalemia, and thrombycytopenia. Four patients underwent orthotopic liver transplant. Local control at 6 and 12 months were 90% [95% C.I. (55.5%, 99.8%)] and 87.5% [95% C.I. (47.4%, 99.7%)], respectively. Median PFS is 11.0 months (95% CI: 3.9 months, 17.4 months). Ten patients died or progressed including 4 patients who died without progressing. Median TTP is 17.4 months (95% CI: 5.3 months, upper limit not estimable). Median OS is 19.8 months (95% CI: 4.0 months, upper limit not estimable). Conclusions: in carefully selected patients with hepatocellular carcinoma in the context of CPC B liver cirrhosis, score less or equal than 7, SBRT is an effective therapy with a good toxicity profile. Phase II is ongoing.
Randomized phase II trial of cixutumumab (CIX) alone or with cetuximab (CET) for refractory recurrent/metastatic squamous cancer of head and neck (R/M-SCCHN).
Authors: Bonnie S. Glisson, Jennifer Tseng, Shanthi Marur, Dong M Shin, Barbara A. Murphy, Ezra E.W. Cohen, Christopher Y. Thomas, Richard Willey, Jan Cosaert, William Nassib William, Nusrat Harun, J. Jack Lee, Robert I. Haddad
Journal: Journal of Clinical Oncology (2013)

6030 Background: Preclinical evidence supports clinical investigation of IGF-1R inhibitors alone, or combined with EGFR inhibitors, in SCCHN patients (pts). CIX and CET monoclonal antibodies block ligand binding to IGF-1R and EGFR, respectively. CIX mono and CIX+CET combo were studied in pts with chemotherapy-refractory R/M-SCCHN. Methods: This open-label phase II trial randomized 97 pts with R/M-SCCHN, ECOG PS 0-2 and disease progression following (&lt;90 days) platinum-based chemotherapy, to CIX 10 mg/kg alone (Arm A) or with CET 500 mg/m 2 (Arm B) every 2 wks. Time to recurrence from last anti-EGFR exposure had to be &gt;90 days; pts were stratified by prior CET exposure. Primary endpoint was median PFS (RECIST assessments every 8 wks). Efficacy endpoints in the CET-naïve patients, immunohistochemical analysis of 10 relevant markers on tumor specimens, and cytokine/angiogenic factor profiling of blood samples obtained serially through treatment were also examined. Results: 47 Arm A and 44 arm B pts were treated: median age: 60.0 y (35 - 81), PS 0/1/2: 17.6%/62.6%/19.8%, male (80.2%), tumors originating mainly from oropharynx (67.1%), supraglottic (9.9%) and oral cavity (13.2%), with 33% moderately and 36.3% poorly differentiated tumors, previous therapy: 98.9% chemotherapy and 82.4% radiotherapy indicating no baseline differences. Most common tx-emergent AEs were fatigue (55.3 vs. 61.4%), dermatitis acneiform (6.4 vs 63.6%), nausea (29.8 vs. 34.1%), weight decreased (25.5 vs. 29.5%), hyperglycemia (25.5% vs. 29.5%), vomiting (21.3 vs. 20.5%), and headache (17 vs. 25%). Efficacy: See Table. Conclusions: Targeting IGF-1R alone with CIX or co-targeting IGF-1R and EGFR with CIX and CET did not result in improved PFS compared to historical data with CET alone in patients with chemotherapy-refractory R/M-SCCHN. The results of this study do not support CIX single-agent activity in this patient population. Therapy on both arms was feasible. There was no apparent exacerbation of CET toxicity by concurrent CIX exposure. Clinical trial information: NCT00617734. [Table: see text]
Suppression of Mir-708 Promotes DKK3 to Inhibit Wnt/β-Catenin Signaling Pathway in Adult B-ALL
Authors: Yingjie Zhang, Huibo Li, Rongyi Cao, Lili Sun, Yan Wang, Shengjin Fan, Yanqiu Zhao, Desheng Kong, Lin Cui, Leilei Lin, Ke Wang, Chen Wang, Yinghua Li, Jin Zhou
Journal: Blood (2016)
Dasatinib first-line treatment in gastrointestinal stromal tumors: A multicenter phase II trial of the SAKK (SAKK 56/07).
Authors: Michael Montemurro, Julien Domont, Aurore Blesius, Piotr Rutkowski, Arnaud Roth, Roger Von Moos, Roman Ignaz Inauen, Binh Bui Nguyen, Roger Burkhard, Claudio Knusli, Sebastian Bauer, Philippe A Cassier, Heike Schwarb, Axel Le Cesne, Dieter Koeberle, Vincent Dunet, Daniel Dietrich, Christine Biaggi, John Prior, Serge Leyvraz
Journal: Journal of Clinical Oncology (2012)

10033 Background: First line imatinib has improved the outcome of patients (pts) with gastrointestinal stromal tumor (GIST), but primary and secondary resistance remain a problem. Dasatinib is a second generation tyrosine kinase inhibitor (TKI) and inhibits the activity of bcr-abl, src-family kinases along with a number of other oncogenic kinases including kit. In vitro, dasatinib has shown activity against imatinib-resistant cell lines. Routinely, pts diagnosed with GIST and treated with TKIs are monitored by computed tomography (CT). 18F-fluorodeoxyglucose positron-emission-tomography (FDG-PET) measures tumor metabolic activity for early response assessment, which might be of particular use in the clinical trial setting. Methods: This two-stage phase II trial investigated dasatinib in pts with TKI-naïve GIST. Dasatinib starting dose was 2x70mg/day in pts with histologically proven, FDG-PET positive GIST. Response evaluation was done by serial CT and FDG-PET using EORTC PET response criteria (Young et al. 1999). Elective surgery was allowed after 6 months of trial treatment. Primary endpoint was response (CR+PR) by FDG-PET after one month of dasatinib. Results: 47 of planned 52 pts have been enrolled from December 2007 to November 2011, when the trial was terminated due to slow accrual. 43 pts were eligible. Median age was 61 years, 24 pts were male, 19 female and 41 had a performance status of 0 or 1. At a median follow-up of 11.9 months, 20 pts were still on treatment. Pts went off trial for elective surgery (n=6), progression (n=11), toxicity (n=3), and three patients died (one on-drug). 5% of pts experienced G4, and 38% of pts G3 toxicity, which were most often gastrointestinal or pulmonary. 28% had their dose reduced or interrupted. The primary endpoint, FDG-PET response rate (CR+PR) at 4 weeks was 67% (13 CR, 16 PR, 7 SD, 3 PD, 4 not evaluable). Median progression-free survival is 11.1 months and median overall survival not yet reached. Conclusions: Dasatinib shows promising efficacy in TKI-naïve pts with FDG-PET positive GIST. Mutational data will be presented at the meeting.
IGHV Mutational Status Is Prognostic in Del(11q) and Del(17p) Chronic Lymphocytic Leukemia
Authors: Douglas Edward Gladstone, Amanda Blackford, Yvette L. Kasamon, Lode J. Swinnen, Javier Bolanos Meade, Christopher Gocke, Constance Griffin, Richard J. Jones
Journal: Blood (2011)
PKA-Mediated Phosphorylation of APOBEC3B Suppresses Its DNA Mutagenic Potential in Myeloma Cells
Authors: Tadahiko Matsumoto, Kotaro Shirakawa, Hiroyuki Matsui, Hiroyuki Yamazaki, Yasuhiro Kazuma, Anamaria Daniela Sarca, Hirofumi Fukuda, Wataru Maruyama, Akifumi Takaori-Kondo
Journal: Blood (2016)
Abdominal Edema and Inflammation in a Ventilator-Induced Lung Injury Model : Comparison Between Spontaneous Breathing and Mechanical Ventilation
Authors: Silvia Marchesi, Aki Hata, Anders Larsson, Göran Hedenstierna
Journal: American Journal of Respiratory and Critical Care Medicine (2016)

RATIONALE. The amount of abdominal edema and inflammation were investigated in a porcine model of ventilator-induced lung injury,VILI, and potential differences between spontaneously breathing and  ...
UNIVERSAL USE OF CONTRAST TO DETECT LEFT VENTRICULAR THROMBUS IN PATIENTS WITH REDUCED EJECTION FRACTION IS NOT ASSOCIATED WITH IMPROVED CLINICAL OR COST-EFFECTIVENESS OUTCOMES
Authors: E. Philip Lehman, Patricia Cowper, Tiffany Randolph, Andrzej Kosinski, Ranato D. Lopes, Pamela Douglas
Journal: Journal of the American College of Cardiology (2017)
A randomized phase II study of androgen deprivation therapy with or without PD0332991 in RB-positive metastatic hormone-sensitive prostate cancer.
Authors: Phillip Lee Palmbos, Felix Yi-Chung Feng, Scott A. Tomlins, William Kevin Kelly, Alicia Katherine Morgans, Mary-Ellen Taplin, Neeraj Agarwal, Emmanuel S. Antonarakis, Przemyslaw Twardowski, Jon Jacobson, Matthew S. Davenport, Stephanie Daignault, Karen E. Knudsen, Maha Hussain
Journal: Journal of Clinical Oncology (2015)

TPS5074 Background: Androgens drive proliferation of prostate cancer cells via upregulation of cyclin D which complexes with the CDK4/6 kinases, resulting in phosphorylation of Rb and G1/S progression. Perturbations in this pathway (loss of Rb, upregulation of cyclin D) are felt to promote castration-resistance. PD0332991 (palbociclib) is a novel specific inhibitor of CDK4 and 6. Preclinically PD0332991 inhibited proliferation and promoted G1 arrest in an RB and Cyclin D-dependent manner. 80-90% of early metastatic hormone-sensitive prostate cancers are estimated to retain wild-type RB expression. Addition of PD0332991 to hormonal therapy in ER+ breast tumors demonstrated statistically significant improvements in progression-free survival. Hypothesis: Addition of PD0332991 to initial ADT in patients with newly metastatic RB-positive prostate cancer will significantly increase the efficacy of ADT. Methods: A multicenter randomized phase II study of PD0332991 was initiated (NCT02059213) in which patients (n = 60) with new metastatic hormone sensitive prostate cancer and RB intact tumors based on metastatic biopsy are stratified by disease extent and randomized (1:2) to ADT or ADT plus PD0332991. Primary endpoint is PSA response ( < 4 ng/mL) after 7 months of therapy. With 20 patients randomized to ADT and 40 randomized to ADT plus PD0332991 there will be a 64.2% power to detect a 20% difference in proportions with a one-sided type I error of 0.10 using the mid p-value method of the Fisher’s exact test. Secondary endpoints: safety and tolerability of ADT + PD0332991, rate of undetectable PSA ( < 0.2ng/mL), biochemical and clinical progression-free survival, overall PSA and radiographic response rates, assessment of biomarkers which predict therapy response (circulating DNA and tumor cells, tumor protein and transcriptome analysis) and to establish a repository of metastatic hormone sensitive prostate tumor samples. Support: Movember-PCF Challenge Award, Pfizer. Clinical trial information: NCT02059213.
Optimal tolerance of an all-oral combination chemotherapy (CT) of oral vinorelbine (NVBo), capecitabine (C) with/without trastuzumab (T) in metastatic breast cancer (MBC) patients (pts): Safety Results of two international multicenter studies
Authors: A. Chan, N. Tubiana, V. Ganju, P. Conte, P. Bougnoux, D. Aubert, T. Bourlard, D. Becquart
Journal: Journal of Clinical Oncology (2006)

10607 Background: Combination therapy of T and Vinorelbine has recently been reported to be an active and safe regimen for HER2 positive MBC pts. The current safety analysis investigated NBVo and C, which offers the convenience of an all-oral regimen given alone or in combination with T, if pts were HER2 positive, as first-line therapy for MBC patients, KPS ≥ 70%. Methods: In the HER2 negative study ([A]) (IHC 0- 2+/FISH−) 38 pts received: NVBo 60 mg/m 2 (Cycle 1) or 80 mg/m 2 (from Cycle 2) D1 &amp; D8 and C 2000 (1500 if ≥ 65 y) mg/m 2 /d D1-D14 every 3 weeks. In the HER2 positive study ([B]) (IHC 2+ or 3+ confirmed by FISH+) 25 pts received : NVBo, and C at the same doses as [A] + T, 4 mg/kg on D 1 as loading dose and then 2 mg/kg i.v. weekly starting on D8. Treatment was continued in both studies till progression. Results: Median age: [A] 61.5y (17 pts ≥ 65 y), [B] 53.0 y (5 pts ≥ 65 y); Prior (neo)adjuvant CT: [A] 21 pts (55.3%), [B] 16 pts (64%); Visceral involvement: [A] 28 pts (73.7%), [B] 22 pts (88%); &gt; 2 metastases: [A] 15 pts (39.5%), [B] 10 pts (40%); Median dose intensity (%): NVBo [A] 45.1 mg/m 2 /w (90.5%), [B] 39.5 mg/m 2 /w (75.7%); C [A] 7733 mg/m 2 /w (87%), [B] 7140 mg/m 2 /w (83.7%); T [B] 2.1 mg/kg/w (98.1%). NVBo dose escalation to 80 mg/ m 2 : [A] 33 pts (94.3%), [B] 23 pts (92%). Tolerance: ([A] n = 38 pts, [B] n = 25 pts) (% of pts with G3/4 NCI CTC v2): Neutropenia [A] 29/16, [B] 52/16; Infection with G3/4 neutropenia [A] 3/3, [B] 8/0; Stomatitis [A] 5/3, [B] 0/4; Bilirubin [A] 3/0, [B] 0/0; HF Syndrome [A] 3/0, [B] 8/0; Nausea [A] 3/0, [B] 0/4; Vomiting [A] 10/0, [B] 4/4; Diarrhoea [A] 5/0, [B] 12/4; Ileus [A] 0/0, [B] 4/0; Febrile Neutropenia: [A] 5%, [B] 8%. Efficacy: the preliminary results on the evaluable pts confirm an optimal disease control (CR + PR + SD): [A] 25/27 pts (92.6%), [B] 22/24 pts (91.7%). Conclusion: The combination of NVBo and C can be safely administered in the palliative setting of MBC and calls for further comparative studies vs i.v. combinations. The addition of T in HER2 positive patients does not alter the favourable safety profile. [Table: see text]
Proinflammatory Cytokine Environments Can Drive Interleukin‐17 Overexpression by γ/δ T Cells in Systemic Juvenile Idiopathic Arthritis
Authors: Christoph Kessel, Katrin Lippitz, Toni Weinhage, Claas Hinze, Helmut Wittkowski, Dirk Holzinger, Ndate Fall, Alexei A. Grom, Niklas Gruen, Dirk Foell
Journal: Arthritis & Rheumatology (2017)

Objective Systemic‐onset juvenile idiopathic arthritis (JIA) is speculated to follow a biphasic course, with an initial systemic disease phase driven by innate immune mechanisms and interleukin‐1β (IL‐1β) as a key cytokine and a second chronic arthritic phase that may be dominated by adaptive immunity and cytokines such as IL‐17A. Although a recent mouse model points to a critical role of IL‐17–expressing γ/δ T cells in disease pathology, in humans, both the prevalence of IL‐17 and the role of IL‐17–producing cells are still unclear. Methods Serum samples from systemic JIA patients and healthy pediatric controls were analyzed for the levels of IL‐17A and related cytokines. Whole blood samples were studied for cellular expression of IL‐17 and interferon‐γ (IFNγ). CD4+ and γ/δ T cells isolated from the patients and controls were assayed for cytokine secretion in different culture systems. Results IL‐17A was prevalent in sera from patients with active systemic JIA, while both ex vivo and in vitro experiments revealed that γ/δ T cells overexpressed this cytokine. This was not seen with CD4+ T cells, which expressed strikingly low levels of IFNγ. Therapeutic IL‐1 blockade was associated with partial normalization of both cytokine expression phenotypes. Furthermore, culturing healthy donor γ/δ T cells in serum from systemic JIA patients or in medium spiked with IL‐1β, IL‐18, and S100A12 induced IL‐17 overexpression at levels similar to those observed in the patients' cells. Conclusion A systemic JIA cytokine environment may prime γ/δ T cells in particular for IL‐17A overexpression. Thus, our observations in systemic JIA patients strongly support a pathophysiologic role of these cells, as proposed by the recent murine model.
MORE BLEEDING AND MYOCARDIAL INFARCTIONS POST-PCI IN PATIENTS WITH BMI OVER 30
Authors: Perwaiz M. Meraj, Rajkumar Doshi, Bhavitha George, Lakhbir Kaur, Abhishek Vadher, Amitkumar Patel, Varun Jauhar
Journal: Journal of the American College of Cardiology (2017)